Merck Enhances Aura Of Cancer Research With Vertex Aurora Kinase Inhibitor Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
VX-680 is ready to begin Phase I trials; aurora kinase inhibitor could have applicability in a number of cancer types. Merck will pay $20 mil. up front and as much as $350 mil. in milestones to Vertex.